Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Ultra-long-acting in-situ forming implant (ISFI) as a subcutaneous injection for prevention of HIV and unplanned pregnancy

Award Number: R61AI197035
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/14/2026
PERIOD OF PERFORMANCE END DATE: 03/31/2028

Group Awards By:

View Award Description

Ultra-long-acting in-situ forming implant (ISFI) as a subcutaneous injection for prevention of HIV and unplanned pregnancy - Globally, over 50% of those infected with HIV are women, and annually, ~50% of all pregnancies are unplanned. Therefore, there is a critical need to promote female-controlled methods of multipurpose prevention technologies (MPTs) and delivery strategies that can be disassociated from the sex act. Long-acting (LA) formulations that provide sustained drug release over weeks offer several advantages, including relief from “pill fatigue” and better protection of health privacy. As such, LA delivery systems hold great potential to enhance compliance to HIV pre-exposure prophylaxis (PrEP) and help curb the global HIV epidemic. Amongst LA formulations currently in development or recently approved, injectable formulations provide several advantages over implantable devices that require an applicator (e.g. Trocar) or that are sex specific (e.g. vaginal rings, inserts). Injectable formulations are well tolerated by men and women, are efficacious for contraception, and have high patient acceptability and compliance1-4. Apretude, a LA injectable nanoparticle suspensions of cabotegravir (CAB), is the first FDA-approved for HIV PrEP5-7. Although effective, Apretude requires six (6) intramuscular (IM) injections per year after 2 once-monthly starter injections. Lenacapavir (LEN) is another LA injectable currently in Phase 3 clinical trials as a once-every-six-months subcutaneous injection for HIV PrEP8. Despite these advances in HIV PrEP, currently there are no LA injectable MPT formulations in development mainly because of limitations of current LA injectable formulations utilizing nanoparticle suspensions whereby two drugs cannot be combined into a single injection. In this R61/R33 grant and building on our strong preliminary data and current development, we propose a comprehensive evaluation and translation of a first-in-line injectable MPT that offers durable and sustained protection from HIV transmission, high efficacy of contraception, increased user compliance, and the ability to be removed in case of unanticipated adverse events or when considering discontinuation from the LA HIV PrEP and/or contraception. We will achieve this goal by optimizing and advancing a liquid MPT formulation utilizing excipients that form a biodegradable depot after subcutaneous injection (in-situ forming implant (ISFI)). We propose a comprehensive evaluation of this novel drug delivery approach using highly relevant rodent and non-human primate models of safety and pharmacokinetics to support a pre-IND application and meeting with the FDA, tech transfer and GLP manufacturing and scaleup, and initial IND-enabling studies to accelerate its clinical translation. With this cutting-edge combined approach using a unique and highly innovative ultra-long-acting coitally-independent MPT ISFI formulation we will address two significant global unmet needs (HIV and unplanned pregnancy) to make significant impact to global health.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $1,106,984 )
2026	2026	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Allergy and Infectious Diseases Research	000	1	4/17/2026	NEW	$1,106,984
														Subtotal = $1,106,984

Grand Total All Awards = $1,106,984

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Ultra-long-acting in-situ forming implant (ISFI) as a subcutaneous injection for prevention of HIV and unplanned pregnancy

Award Number: R61AI197035

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/14/2026

PERIOD OF PERFORMANCE END DATE: 03/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer